Triple therapy may improve asthma symptoms, particularly among patients requiring systemic corticosteroids to treat severe exacerbations, a study finds. Adding long-acting muscarinic antagonists ...
Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...
Researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation vs glycopyrrolate-formoterol. HealthDay News — Umeclidinium-vilanterol ...
Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...
AERO-007 demonstrated rapid, sustained, statistically significant, and clinically meaningful bronchodilation through 24 hours in patients with moderate-to-severe COPD Treatment with AERO-007 was well ...
Please provide your email address to receive an email when new articles are posted on . There is a need for a nebulized LABA/LAMA formulation in COPD. Bronchodilation, pharmacokinetics and safety of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results